-
公开(公告)号：US12109203B2
公开(公告)日：2024-10-08
申请号：US17262278
申请日：2019-07-24
发明人： Ranjit Desai , Vrajesh Pandya , Mehul Pujara , Anil Argade , Jignesh Joshi , Anshul Satyanand
IPC分类号： A61K31/438 , A61K31/133 , A61K31/4409 , A61K31/454 , A61K31/496 , A61K31/4965 , A61K31/5383 , A61K31/606 , A61K31/7036 , A61P31/04 , C07D413/14 , C07D491/107 , C07D495/10
CPC分类号： A61K31/438 , A61K31/133 , A61K31/4409 , A61K31/454 , A61K31/496 , A61K31/4965 , A61K31/5383 , A61K31/606 , A61K31/7036 , A61P31/04 , C07D413/14 , C07D491/107 , C07D495/10
摘要： Present invention relates to novel compound of formula (I), their enantiomers, their diastereomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment of bacterial infection.
-
公开(公告)号：US20240325387A1
公开(公告)日：2024-10-03
申请号：US18423815
申请日：2024-01-26
IPC分类号： A61K31/4965 , A61K31/438 , A61K31/4545 , A61K31/47 , A61K31/498 , A61P31/06
CPC分类号： A61K31/4965 , A61K31/438 , A61K31/4545 , A61K31/47 , A61K31/498 , A61P31/06
摘要： The present invention relates to novel combinations, which are useful in the treatment of tuberculosis.
-
公开(公告)号：US20240307382A1
公开(公告)日：2024-09-19
申请号：US18330185
申请日：2023-06-06
发明人： Kathleen Ann Martin , Carmela Sidrauski , Jennifer M. Frost , Marina Pliushchev , Yunsong Tong , Lawrence A. Black , Xiangdong Xu , Lei Shi , Qingwei Zhang , SeungWon Chung , Ramzi Farah Sweis , Michael J. Dart , John T. Randolph , Kathleen J. Murauski
IPC分类号： A61K31/4965 , A61K31/196 , A61K31/341 , A61K31/36 , A61K31/381 , A61K31/415 , A61K31/4196 , A61K31/42 , A61K31/421 , A61K31/422 , A61K31/4245 , A61K31/425 , A61K31/426 , A61K31/437 , A61K31/4427 , A61K31/472 , A61K31/4985 , A61K31/519 , A61K31/5355 , A61K45/06 , C07C233/62 , C07D217/26 , C07D231/14 , C07D237/20 , C07D241/20 , C07D249/10 , C07D261/18 , C07D263/34 , C07D275/03 , C07D277/56 , C07D285/06 , C07D307/68 , C07D317/46 , C07D333/38 , C07D401/04 , C07D413/04 , C07D471/04 , C07D487/04 , C07D495/04
CPC分类号： A61K31/4965 , A61K31/196 , A61K31/341 , A61K31/36 , A61K31/381 , A61K31/415 , A61K31/4196 , A61K31/42 , A61K31/421 , A61K31/422 , A61K31/4245 , A61K31/425 , A61K31/426 , A61K31/437 , A61K31/4427 , A61K31/472 , A61K31/4985 , A61K31/519 , A61K31/5355 , A61K45/06 , C07C233/62 , C07D217/26 , C07D231/14 , C07D237/20 , C07D241/20 , C07D249/10 , C07D261/18 , C07D263/34 , C07D275/03 , C07D277/56 , C07D285/06 , C07D307/68 , C07D317/46 , C07D333/38 , C07D401/04 , C07D413/04 , C07D471/04 , C07D487/04 , C07D495/04
摘要： Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
-
公开(公告)号：US12077605B2
公开(公告)日：2024-09-03
申请号：US18157293
申请日：2023-01-20
发明人： Wolfgang Richter , Muhammad Abbas , Lutz Weber , Amit Kumar
IPC分类号： C07K5/087 , A61K31/245 , A61K31/404 , A61K31/427 , A61K31/4418 , A61K31/496 , A61K31/4965 , A61K31/513 , A61K31/519 , A61K31/635 , A61K31/675 , A61K31/7056 , A61K31/7064 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K36/746 , A61K38/06 , A61P31/14
CPC分类号： C07K5/0812 , A61K31/245 , A61K31/404 , A61K31/427 , A61K31/4418 , A61K31/496 , A61K31/4965 , A61K31/513 , A61K31/519 , A61K31/635 , A61K31/675 , A61K31/7056 , A61K31/7064 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K36/746 , A61K38/06 , A61P31/14
摘要： Described herein are Mpro cysteine protease inhibitors and methods of utilizing such inhibitors in the treatment of diseases, disorders, or conditions. Also described herein are pharmaceutical compositions containing such compounds.
-
公开(公告)号：US20240216365A1
公开(公告)日：2024-07-04
申请号：US18542451
申请日：2023-12-15
发明人： Vikas Anathy , Nicolas Chamberlain , Amit Kumar
IPC分类号： A61K31/496 , A61K31/381 , A61K31/427 , A61K31/4965 , A61K31/675 , A61K31/7048 , A61K31/7068 , A61K35/16 , A61K39/395 , A61K39/42 , A61P31/14 , C07K16/40 , C12N15/113 , G01N33/50
CPC分类号： A61K31/496 , A61K31/381 , A61K31/427 , A61K31/4965 , A61K31/675 , A61K31/7048 , A61K31/7068 , A61K35/16 , A61K39/3955 , A61K39/42 , A61P31/14 , C07K16/40 , C12N15/1137 , G01N33/5008 , C12N2310/14
摘要： Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.
-
公开(公告)号：US20240180880A1
公开(公告)日：2024-06-06
申请号：US18454612
申请日：2023-08-23
申请人： Epizyme, Inc.
IPC分类号： A61K31/4184 , A61K31/155 , A61K31/165 , A61K31/167 , A61K31/17 , A61K31/198 , A61K31/4045 , A61K31/407 , A61K31/4192 , A61K31/428 , A61K31/437 , A61K31/4406 , A61K31/454 , A61K31/4709 , A61K31/496 , A61K31/4965 , A61K31/4985 , A61K31/506 , A61K31/519 , A61K31/706 , A61K38/46 , A61P7/06 , C07C211/44 , C07C211/45 , C07C211/46 , C07C211/47 , C07C211/48
CPC分类号： A61K31/4184 , A61K31/155 , A61K31/165 , A61K31/167 , A61K31/17 , A61K31/198 , A61K31/4045 , A61K31/407 , A61K31/4192 , A61K31/428 , A61K31/437 , A61K31/4406 , A61K31/454 , A61K31/4709 , A61K31/496 , A61K31/4965 , A61K31/4985 , A61K31/506 , A61K31/519 , A61K31/706 , A61K38/465 , A61P7/06 , C07C211/44 , C07C211/45 , C07C211/46 , C07C211/47 , C07C211/48
摘要： The present disclosure relates to a method of preventing or treating a blood disorder (e.g., sickle-cell disease) via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
-
公开(公告)号：US20240115664A1
公开(公告)日：2024-04-11
申请号：US18524116
申请日：2023-11-30
申请人： MannKind Corporation
IPC分类号： A61K38/28 , A61K9/00 , A61K9/16 , A61K9/48 , A61K31/357 , A61K31/4965 , A61K31/535 , A61K47/22 , C07D241/02 , C07D241/08
CPC分类号： A61K38/28 , A61K9/0053 , A61K9/0075 , A61K9/1617 , A61K9/1682 , A61K9/4858 , A61K31/357 , A61K31/4965 , A61K31/535 , A61K47/22 , C07D241/02 , C07D241/08 , Y02P20/582
摘要： Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization.
-
公开(公告)号：US11923511B2
公开(公告)日：2024-03-05
申请号：US16925755
申请日：2020-07-10
发明人： Yufei Wang , John S. Miller , John Hession , Arden P Johnson
IPC分类号： H01M10/0587 , A61K31/433 , A61K31/44 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4965 , A61K31/497 , A61K31/501 , A61K31/505 , A61K31/506 , A61K45/06 , C07D213/75 , C07D239/42 , C07D241/20 , C07D285/135 , C07D401/04 , C07D401/12 , C07D417/06 , C07D417/08 , C07D417/14 , H01M4/134 , H01M4/36 , H01M4/38 , H01M4/58 , H01M4/62 , H01M4/66 , H01M10/052 , H01M10/0568 , H01M10/0569 , H01M50/119 , H01M50/131 , H01M50/138 , H01M50/148 , H01M50/159 , H01M50/186 , H01M50/188 , H01M50/191 , H01M50/466
CPC分类号： H01M10/0587 , A61K31/433 , A61K31/44 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4965 , A61K31/497 , A61K31/501 , A61K31/505 , A61K31/506 , A61K45/06 , C07D213/75 , C07D239/42 , C07D241/20 , C07D285/135 , C07D401/04 , C07D401/12 , C07D417/06 , C07D417/08 , C07D417/14 , H01M4/134 , H01M4/368 , H01M4/382 , H01M4/582 , H01M4/623 , H01M4/625 , H01M4/662 , H01M10/052 , H01M10/0568 , H01M10/0569 , H01M50/119 , H01M50/138 , H01M50/1535 , H01M50/159 , H01M50/186 , H01M50/188 , H01M50/191 , H01M50/466 , H01M50/131 , H01M2300/0031 , Y02A50/30
摘要： A novel wound electrode assembly for a lithium oxyhalide electrochemical cell is described. The electrode assembly comprises an elongate cathode of an electrochemically non-active but electrically conductive carbonaceous material disposed between an inner elongate portion and an outer elongate portion of a unitary lithium anode. That way, lithium faces the entire length of the opposed major sides of the cathode. This inner anode portion/cathode/outer anode portion configuration is rolled into a wound-shaped electrode assembly that is housed inside a cylindrically-shaped casing. A cylindrically-shaped sheet-type spring centered in the electrode assembly presses outwardly to limit axial movement of the electrode assembly. In one embodiment, all the non-active components, except for the cathode current collector which is nickel, are made of stainless-steel. This provides the cell with a low magnetic signature without adversely affecting the cell's high-rate capability.
-
公开(公告)号：US11883395B2
公开(公告)日：2024-01-30
申请号：US17320069
申请日：2021-05-13
发明人： Vikas Anathy , Nicolas Chamberlain , Amit Kumar
IPC分类号： A61K31/496 , C07K16/40 , A61K31/381 , A61K31/427 , A61K31/675 , A61K31/7068 , A61K39/395 , A61K31/4965 , A61K31/7048 , C12N15/113 , A61K35/16 , A61K39/42 , A61P31/14 , G01N33/50
CPC分类号： A61K31/496 , A61K31/381 , A61K31/427 , A61K31/4965 , A61K31/675 , A61K31/7048 , A61K31/7068 , A61K35/16 , A61K39/3955 , A61K39/42 , A61P31/14 , C07K16/40 , C12N15/1137 , G01N33/5008 , C12N2310/14
摘要： Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.
-
公开(公告)号：US20240000789A1
公开(公告)日：2024-01-04
申请号：US17998391
申请日：2021-05-11
申请人： NOVARTIS AG
IPC分类号： A61K31/5377 , A61K31/4965 , A61K31/519 , A61P35/00 , A61P35/04
CPC分类号： A61K31/5377 , A61K31/4965 , A61P35/04 , A61P35/00 , A61K31/519
摘要： The present invention provides a pharmaceutical combination comprising a CRAF inhibitor in combination with (i) an ERK inhibitor or (ii) a MEK inhibitor or (iii) a CDK4/6 inhibitor, each as defined herein, or independently in each case a pharmaceutically acceptable salt thereof, for use in the treatment of NRAS-mutant melanoma and in the treatment of BRAF-mutant melanoma. wherein the melanoma may be unresectable and/or metastatic melanoma.
-
-
-
-
-
-
-
-
-
搜索结果
1438 条记录 (耗时 0.031 秒)
